- Home
- TLRY vs GYRE Comparison
TLRY vs GYRE Comparison
Compare TLRY & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLRY | GYRE |
|---|---|---|
| Founded | N/A | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.9M | 679.4M |
| IPO Year | 2018 | 2004 |
Fundamental Metrics
Financial Performance| Metric | TLRY | GYRE |
|---|---|---|
| Price | $5.31 | $6.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $72.33 | $17.00 |
| AVG Volume (30 Days) | ★ 7.0M | 59.0K |
| Earning Date | 04-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $275,000.00 |
| Revenue This Year | $8.79 | $19.88 |
| Revenue Next Year | $19.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $6.58 |
| 52 Week High | $15.70 | $11.61 |
Technical Indicators
Market Signals| Indicator | TLRY | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 32.23 | 37.19 |
| Support Level | $1.12 | N/A |
| Resistance Level | $7.01 | $8.26 |
| Average True Range (ATR) | 0.25 | 0.38 |
| MACD | -0.07 | -0.10 |
| Stochastic Oscillator | 4.99 | 3.27 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.